News

Pfizer Inc. announced that the US Food and Drug Administration (FDA) accepted for filing the company’s New Drug Applications (NDAs) for tafamidis for the treatment of transthyretin…
Read More...

BioMed X announced a new crowdsourcing project within its framework collaboration with Boehringer Ingelheim. BioMed X and Boehringer Ingelheim started their partnership in 2014 and…
Read More...

Aerpio Pharmaceuticals announced the completion of patient dosing in the Company’s TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead…
Read More...

Zymeworks reported the achievement of a new development milestone in its collaboration with Eli Lilly and Company. In accordance with Zymeworks’ 2014 licensing and collaboration…
Read More...

Lipocine Inc. announced approximately eight-week top-line interim results from an ongoing sixteen-week Liver Fat Imaging study ("Liver Fat Study") with LPCN 1144. The Liver Fat Study is…
Read More...

Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse platform technology for antibody drug discovery, announced the expansion of its existing non-exclusive…
Read More...

AIVITA Biomedical announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1B clinical trial investigating the…
Read More...

Nexus Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) approval of Busulfan Injection, the company's AP-rated therapeutic equivalent for Busulfex 60 mg/10…
Read More...

Luye Pharma has announced it has entered an agreement with AstraZeneca China, the terms of which grant AstraZeneca China exclusive rights to promote Luye Pharma's Xuezhikang Capsules in…
Read More...

Phoenix Molecular Designs announced that it has entered into a collaboration with Roche to develop a diagnostic (CDx) in triple-negative breast cancer (TNBC). The Roche CDx identifies…
Read More...

The U.S. Food and Drug Administration approved the first generic version of Sabril (vigabatrin) 500 mg tablets for treating complex partial seizures, also called focal seizures, as an…
Read More...

Abbott announced that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical device company developing a less-invasive heart valve replacement…
Read More...

Silence Therapeutics announces that its lead medicine candidate SLN124 has been granted Orphan Drug Designation by the Committee for Orphan Medicinal Products (COMP), the European…
Read More...

Cobra Biologics announced the appointment of Dr Darrell Sleep as Director of Innovation. The appointment is part of on-going strategic expansion activities currently underway at Cobra’s…
Read More...

Exelixis announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX (cabozantinib) tablets for patients with hepatocellular carcinoma (HCC) who have been previously…
Read More...

Puma Biotechnology announced that it has entered into an exclusive License Agreement with Knight Therapeutics Inc. that grants Knight the exclusive right to commercialize NERLYNX…
Read More...

SAMDI Tech, Inc., the industry’s leading provider of label-free drug discovery solutions, has promoted Michael D. Scholle to chief operating officer. Formerly serving as director and…
Read More...

SIRION Biotech GmbH announced that it signed a license and collaboration agreement with Denali Therapeutics, a biopharmaceutical company developing a broad portfolio of product…
Read More...

Clinigen Group plc announces that its Clinical Trial Service business has extended its exclusive European clinical trial supply agreement with Accord Healthcare. Clinigen is also…
Read More...

Selexis SA announced that it has signed additional commercial license agreements (CLAs) with Agenus, an immuno-oncology company with a pipeline of immune-modulating antibodies, cancer…
Read More...